Tumor relapse with its attendant acquired cellular resistance to chemotherapy is the scourge of cancer treatment. Generally, once relapse occurs the prognosis is poor. There are classical reasons for resistance that include altered membrane transport, mutation of the target, drug degradation, or failure to promote apoptosis 1,2 . Recently, in addition to the classical models of resistance, much attention is being paid to cancer stem cells 3 . Arguably, the role of cancer stem cells in tumor relapse is best understood for acute myelogenous leukemia, largely because of the pioneering studies of Dick and colleagues 4 . These stem cells are thought to constitute a reservoir of tumor cells that are resistant to chemotherapy because of their capacity for self-renewal and relatively low rate of entry into the cell cycle 3 . Thus, when cancer relapses the tumor may be composed largely of stem cells because the process of chemotherapy selects for them. Here, we show that an agonist antibody that induces AML cells to kill each other is highly selective for relapsed cells. This occurs likely because the chemotherapy process selected for a population of stem cells that constitute the relapsed tumor and, in terms of induction of a new phenotype, stem cells are the preferred target for the agonist antibody.
www.nature.com/scientificreports www.nature.com/scientificreports/ this antibody to the TPOR induces normal CD34 + cells to differentiate into megakaryocytes and platelets in vitro and in vivo and no killer cells are seen 9, 11 . One criticism of our work could be couched in terms of medical need and the resistance of cells that recur after treatment to any therapy. Thus, in their armamentarium oncologists have plenty of drugs to eliminate some primary tumors and the real problem is when the tumor relapses. The cells in a relapsed tumor, by definition, have been selected to resist therapy. Some oncologists expected resistance to be a general property such that these relapsed cells would also be largely resistant to other therapeutic modalities including the agonist antibody. We, however, expected just the opposite and predicted an inversion from that which is usually seen in that the antibody would be more effective on relapsed tumors. The logic was that the recurrent cells are more stem cell like and stem cells are the very "substrate" of the agonist antibody. Actually, the stem cell phenotype is obligatory for induction. Here we show that, indeed, our therapeutic antibody shows an inversion from that seen in classical cancer therapy in that it kills recurrent tumor cells much more efficiently than cells of the primary tumor. Thus, there could be a new paradigm for cancer therapy where during chemotherapy there is an actual selection of cells that are sensitive to the next therapeutic modality and one needs to search for antibodies that selectively kill cell populations selected by chemotherapy.
Results

An antibody that potently induces differentiation of relapsed AML cells. AML is a hematological
malignancy characterized by the presence of specific cell types and outcomes 12 . AML is associated with poor long-term survival, even when newer chemotherapeutic agents are used. Recent studies have reported that the AML relapse and resistance to conventional chemotherapies may originate from a small population, known as AML stem cells 4 . Given that we had generated an agonist antibody that induced differentiation of bone marrow stem cells, we wondered whether the responsiveness of a population of AML cells to the antibody could be changed after chemotherapy 9 . To compare the size of the stem cell populations between newly diagnosed and relapse, we used patient samples from 3 newly diagnosed and 3 relapsed AML patients. Two of the samples from the newly diagnosed AML patients were classified according to accepted standards as M1 (without maturation), and other was M2 (acute myeloblastic leukemia with maturation) whereas in the case of relapsed AML, one sample was classified as M1 and the other two were M2.
It is known that some AML stem cells are CD34 + /CD38 −13,14 . To quantitate this population of stem cells in the AML samples, we carried out Fluorescence-activated cell sorting (FACS) analysis after fluorescent cell surface labeling of CD34 and CD38 markers. According to the FACS analysis, in the three cases of relapsed AML the CD34
− population of cells was about 2.5 fold higher than that of newly diagnosed AML cells (Fig. 1a, b ). Based on this observation, we hypothesized that the relapsed AML cell population may be more susceptible to agonist antibody-induced killer cell differentiation because, as noted above, the stem cell phenotype is an obligatory component of the mechanism of action of the antibody. Thus, we next tested whether the agonist antibody can induce killer cell phenotypes even in relapsed AML cells. First, we checked whether TPOR is expressed in several AML subsets and found that TPOR is abundantly expressed both in newly diagnosed and relapsed AML cells ( Supplementary Fig. S1 ). When the relapsed AML cells were incubated with the agonist antibody, they were also attached to the culture dish and formed multiple short filopodia (Fig. 1d) . Nearly no cells adhered to dish in the absence of the agonist antibody (Fig. 1c) . In the course of several experiments we found that the majority of cells from relapsed AML patients fully differentiate into killer cells after 4 days (Fig. 1d) . Figure 1e , f represent the magnified images of fully differentiated cells in Fig. 1d . During this time the short filopodia from cells of the initial phase were further elongated and the cells began to express Perforin and Granzyme B abundantly (Fig. 1d-f , Supplementary Fig. S2 ).
the Agonist antibody preferentially causes relapsed AML cells to be killed. To gain quantitative information about the responsiveness of AML cells against the agonist antibody, we quantitated the number of cells induced to become killer cells in the relapsed versus starting AML population. After 6 days induction, relapsed AML cells are converted to killer cells about 2 times more than newly diagnosed AML cells (Fig. 1g) . To determine if the increase in the number of killer cells affects the killing potential of the population, we measured the cytotoxic activity of these antibody-induced killer cells. Induced killer cells from a newly diagnosed AML cell population reduced the cell viability by 30% in 24 hr. By contrast, 50% of cells from the relapsed AML population were killed (Fig. 1h) . These data again suggest that the relapsed AML cell population is more susceptible to induction of differentiation by the agonist antibody. single cell studies. Since all previous studies were carried out on cell populations, we wished to observe the killing process on relapsed AML cells at the single cell level. We observed that initially many more cells from the relapsed as compared to the newly diagnosed AML population attach to the dish. These attached cells then develop long filopodia that capture the target cells as yet undifferentiated AML cells (Fig. 2a) . Clearly these differentiating cells arise from cells that have a very different morphology from the starting AML cells. To ensure that the filopodia based cell attachment to target cells is actually followed by death of the target cells we studied the process using time lapsed microscopy. We showed that attachment of these actively moving long filopodia from killer cells is followed by explosive rupture of the captured target cells ( www.nature.com/scientificreports www.nature.com/scientificreports/ phosphorylation in the newly diagnosed AML cell population. Similarly, in relapsed AML cells the antibody again potently activates AKT and ERK compared to induction with natural TPO (Fig. 3a, b) . To analyze the signaling pathways required for killer cell induction by agonist antibody, relapsed AML cells were co-treated with agonist antibody and chemical inhibitors of Phosphatidylinositol-3-kinase (PI-3K) or Mitogen-activated protein kinase (MAPK) signaling pathways. Intriguingly, antibody-dependent killer cell induction was inhibited significantly by the inhibitor of PI-3K that are upstream signal of AKT. However, the specific inhibitor of MAPK did not influence the differentiation of cells (Fig. 3c, d ). These observations imply that one of the two main signaling pathways of the TPOR (PI-3K) is critical for the antibody-induced killer cell differentiation from AML cells.
The agonist antibody protects mice in AML xenograft models. To test the efficacy of the agonist antibody in vivo, we first established an AML xenograft model in mice using the NOD/LtSz-scid IL2Rγc null www.nature.com/scientificreports www.nature.com/scientificreports/ (NSG) mice. We studied 6 experimental and 6 control mice. The 4-week-old NSG mice were sub-lethally irradiated 1 day before i.v. injection of 2 million AML cells. Then the mice were treated with the agonist antibody (10 mg/kg) or PBS every other day. The behavior and condition of the mice were routinely analyzed. After 10 days, mice in the non-treated control group began to show evident disease related properties such as ruffled coat, hunched back, weakness and reduced motility but mice in the group treated with antibody did not (Fig. 4a) . By 18 days all mice in the untreated group died but all the mice treated with antibody were still healthy (Fig. 4b) . One of the key findings in AML is the enlargement of organs such as spleen and liver. After sacrificing the mice, we compared the weight of spleen from the control group to the antibody treated group. The spleen weight of antibody treated mice was 50% lower than the untreated control group and comparable to that of normal mice (Fig. 4c) . Furthermore, we analyzed the sections of liver and spleen by H&E and immunohistochemistry to determine if the engrafted AML cells infiltrated into these tissues. The liver and spleen were heavily infiltrated by AML cells (Fig. 4d) . In the liver the infiltrating AML cells localized primarily around portal veins. Importantly, no infiltrating AML cells were observed in mice treated with antibody. These results suggest that the cytotoxicity of the antibody-induced killer cells extends to tumor cells in vivo.
Discussion
The main purpose of this paper is to suggest a new protocol for the treatment of cancer relapse after chemotherapy. It is based on the recent discovery of receptor pleiotropism where one can select many agonist antibodies to known receptors on stem cells that cause them to differentiate along pathways and display phenotypes that differ from the response of these same receptors to their physiological agonists 6, 8, 15 . The central idea is that when cancer relapses after treatment the malignant cell population is enriched for stem cells that are the very cellular substrate for most agonist antibodies. Indeed, stem cells are not simply a preferred but rather are an obligatory target for agonist antibodies.
The concept that control of AML remissions lies in elimination of stem cells is by no means unique to us 9 . The difference is that we suggest an immuno-therapy that relies on inducing differentiation in recurrent AML cells rather than killing them. There are many outcomes that one might wish to happen after an agonist antibody induces an alternative phenotype in cancer stem cells. These range from increased sensitivity to chemotherapy to loss of malignancy in the newly differentiated cells. In the present study, we have an additional advantage because www.nature.com/scientificreports www.nature.com/scientificreports/ treatment with the agonist antibody causes the relapsed AML population to differentiate into killer cells. This is likely to be a special, albeit highly desirable, outcome pejorative to AML stem cells and probably is not generalizable to other cancers. Nevertheless, it would be almost as good if one could select an antibody where the induced differentiation led to loss of the malignant phenotype or increased sensitivity to chemotherapy.
From a practical point of view, all the reagents to test this concept are in place. In principle, one would select from large combinatorial libraries of agonist antibodies that induce phenotypic changes in cancers that recur after chemotherapy. In this scenario, since the chemotherapy selects for stem cells from the original AML population, it is "creating" the substrate for the agonist antibodies. However, in these early times it's not clear whether there are antibody inducible stem cells from different cancers and whether the induced cells are similar even within a given tumor type.
We tested M1 and M2 AML classes from newly diagnosed and relapsed AML patients. According to our experiments, there were no significant difference between M1 and M2 from newly diagnosed or relapsed AML cells regarding differentiation potential and cytotoxicity of killer cells induced by agonist antibody. Furthermore, the CD34
− population also was similar between M1 and M2 AML cells. In the future, it will be intriguing to compare the activity of agonist antibody in other AML classes such as M3 to M7 AML cells. 
by using immunohistochemistry analysis may enhance the elucidation of the in vivo mechanism of antibody action.
A remaining question is what is the definition of a stem cell in the context of agonist antibody treatment? The simple answer is that a stem cell is a cell that is induced to differentiate by the agonist antibody regardless of other parameters. This is an operational definition and may differ from that determined by other parameters such as cell surface markers. To this end, we expect from our morphological studies that, in terms of this definition, the inducible AML stem cell population studied here is much larger than that simply defined by CD34 + and CD38 + cells. Immunocytochemistry. Cells were fixed at room temperature (RT) for 15 min in 4% paraformaldehyde solution, blocked by 5% goat serum and labelled with primary antibodies, followed by fluorescent secondary antibody staining. Hoechst 3342 is from Cell signaling, Rhodamine-phalloidin is from Life technologies. All antibodies were incubated for 1 hr at RT. After washing 3 times with PBS for 5 min, images were analyzed using a confocal microscope. Western blotting. To prepare whole cell lysates, AML cells were washed with PBS twice and then lysed in lysis buffer (10% glycerol, 50 mM NaF, 150 mM NaCl, 1 mM Na 3 VO 4 , 1% Triton X-100, 50 mM HEPES, pH 7.2). The cell lysates were then centrifuged at 12,000 rpm for 5 min at 4 °C to discard aggregates, and the soluble fractions were denatured in LDS sample buffer (5 min at 95 °C, Thermo Fisher Scientific) and then separated by gel electrophoresis (SDS-PAGE). The proteins were electro-transferred to nitrocellulose membranes using the iBlot 2 Gel transfer device system (Invitrogen) and blocked in 5% BSA for 30 min before being incubated with primary antibodies for overnight at 4 °C. After washing the nitrocellulose membranes with PBST for 1 hr, the blots were incubated with horseradish peroxidase-conjugated anti-mouse or anti-rabbit secondary antibody for 1 hr. Then, the membranes were washed with PBST for 30 min and developed by ECL (GE). Anti-ERK1/2 and anti-pERK1/2 (Thr-202/Tyr-204), anti-AKT and anti-pAKT (Thr-308) antibodies were obtained from Cell signaling.
Methods
time-lapse live-cell imaging. Antibody-induced differentiated cells from total population of relapsed
AML cells or CD34
+ /CD38 − relapsed AML cells were co-cultured with undifferentiated target cells in a 96-well plate at 37 °C. The ratio between differentiated cells and target cells were 2:1. Cell images are monitored under bright-field for 6 hr using the In Cell Analyzer 6000 (GE). Cells were cultured in a 5% CO 2 condition.
Xenotransplantation of human leukemic cells. Animals were used in accordance with a protocol reviewed and approved by the Institutional Animal Care and User Ethical Committee of the Scripps Research Institute (Approval #:06-0325). NSG mice were purchased from The Jackson Laboratory. Mice were housed in sterile conditions and fed with irradiated food. 4 weeks old mice were sublethally irradiated with 250 cGy of total body irradiation 24 hr before injection of AML cells. AML cells were washed twice in DPBS and suspended in 200 μl of PBS at a concentration of 2 million cells per mouse for i.v. injection. PBS or agonist antibody (5 mg/kg) was administrated twice per week. Daily monitoring of mice for AML symptoms determined the day of animal euthanization. All methods were carried out in accordance with the relevant guidelines and regulations. statistical analysis. All data are described as mean + / − SE. Statistical analysis was performed using GraphPad prism software (version 7.0, US). Differences between the two groups in terms of continuous variables were analyzed by using the Mann-Whitney test or 2-way ANOVA with Bonferroni's multiple comparison test. Statistical tests used to determine significance are indicated in the figure legends.
